- About
- Advertise
- CureToday.com
- OncLive.com
- OncNursingNews.com
- TargetedOnc.com
- Contact
- Terms and Conditions
- Privacy
- Do Not Sell My Personal Information
© 2023 MJH Life Sciences™ and Cancer Network. All rights reserved.
Ravi Madan, MD | Authors
Ravi A. Madan, MD, Discusses the Significance of the PEACE-1 Trial With Docetaxel, Abiraterone, ADT, and Radiotherapy in mCSPC
October 06, 2021
Ravi A. Madan, MD, discusses the potential impact of docetaxel, abiraterone acetate, androgen deprivation therapy, and radiotherapy on patients with metastatic castration-sensitive prostate cancer.
Ravi Madan, MD, Discusses Key Findings Utilizing PET Imaging and Tc99 Scans in Conjunction With Enzalutamide in mCRPC
September 24, 2021
Ravi Madan, MD, discusses clinical findings utilizing PET imaging and Tc99 scans in patients with metastatic castration-resistant prostate cancer who are being treated with enzalutamide
Advertisement
Advertisement